These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3039 related articles for article (PubMed ID: 6462628)

  • 21. Suicide enzyme inhibition as a chemotherapeutic strategy for controlling metastases derived from intraocular melanomas.
    Niederkorn JY; Sanborn GE; Gamel JW
    Invest Ophthalmol Vis Sci; 1987 Nov; 28(11):1844-50. PubMed ID: 3117718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enucleation and the appearance of second primary tumors in cats bearing virally induced intraocular tumors.
    Niederkorn JY; Shadduck JA; Albert D
    Invest Ophthalmol Vis Sci; 1982 Dec; 23(6):719-25. PubMed ID: 6292123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular metastasis of in vivo and in vitro derived syngeneic murine melanoma.
    Harning R; Szalay J
    Invest Ophthalmol Vis Sci; 1987 Sep; 28(9):1599-604. PubMed ID: 3623843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to melanoma metastases in mice selected for high acute inflammatory response.
    Maria DA; Ribeiro OG; Pizzocaro KF; De Franco M; Cabrera WK; Starobinas N; Gallois V; Siqueira M; Seman M; Ibañez OM
    Carcinogenesis; 2001 Feb; 22(2):337-42. PubMed ID: 11181457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of enucleation in the management of uveal melanomas.
    Zimmerman LE; McLean IW
    Am J Ophthalmol; 1979 Jun; 87(6):741-60. PubMed ID: 377973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
    Ligocki AJ; Brown JR; Niederkorn JY
    J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
    Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
    J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.
    Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR
    J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
    Dace DS; Chen PW; Niederkorn JY
    J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural Killer T Cells Contribute to Neutrophil Recruitment and Ocular Tissue Damage in a Model of Intraocular Tumor Rejection.
    Ligocki AJ; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):813-23. PubMed ID: 26934137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enucleation with stabilization of intraocular pressure in the treatment of uveal melanomas.
    Kramer KK; La Piana FG; Whitmore PV
    Ophthalmic Surg; 1980 Jan; 11(1):39-43. PubMed ID: 7360493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alloantigen presentation to the anterior chamber of the eye subverts specific in vitro cell-mediated immune responses.
    Whittum JA; Niederkorn JY; Streilein JW
    Transplantation; 1982 Oct; 34(4):190-5. PubMed ID: 6183804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous malignant melanoma metastatic to the eye, lids, and orbit.
    Rosenberg C; Finger PT
    Surv Ophthalmol; 2008; 53(3):187-202. PubMed ID: 18501266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival rates after enucleation of eyes with malignant melanoma.
    Seigel D; Myers M; Ferris F; Steinhorn SC
    Am J Ophthalmol; 1979 Jun; 87(6):761-5. PubMed ID: 453304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of no-touch isolation technique for resection of cancer. The eye as a model.
    McCubbin JA; Spratt JS
    Arch Surg; 1980 Feb; 115(2):224-8. PubMed ID: 7356840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
    Hara I; Takechi Y; Houghton AN
    J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 152.